<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15811">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901054</url>
  </required_header>
  <id_info>
    <org_study_id>201605080</org_study_id>
    <nct_id>NCT02901054</nct_id>
  </id_info>
  <brief_title>CSF Pharmacokinetics of Ondansetron</brief_title>
  <official_title>Investigation of Cerebrospinal Fluid (CSF) Pharmacokinetics of Ondansetron</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing
      after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron
      might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by
      investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability
      that may affect that distribution.

      Study procedures will include iv ondansetron administration, serial blood draws,
      cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma and CSF concentrations of ondansetron</measure>
    <time_frame>Prior to infusion, 15, 30, 60, 120, and 180 min from the beginning of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF to plasma concentration ratio</measure>
    <time_frame>15, 30, 60, 120, and 180 min from the beginning of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>open label infusion ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 4-mL CSF sample per subject.
Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>A single 15-min intravenous infusion of ondansetron</description>
    <arm_group_label>open label infusion ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 70 years old;

          2. Patients planned to undergo hip or knee arthroplasty with spinal anesthesia;

          3. Ability to provide informed consent

        Exclusion Criteria:

          1. Not giving consent to participate in the study;

          2. Patients with history of or current hepatic or renal insufficiency;

          3. Patients with BMI â‰¥ 33;

          4. Patients with heart failure or active arrhythmias;

          5. Patients with severe systemic disease that is a constant threat to life;

          6. Contraindication or allergy to ondansetron;

          7. Pregnancy or lactation.

          8. Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Haroutounian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anesthesiology, Washington Univ School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Frey, BS</last_name>
    <phone>314-454-5980</phone>
    <email>freyk@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Haroutounian, PhD</last_name>
    <phone>314-286-1715</phone>
    <email>sharout@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Haroutounian, PHD</last_name>
      <phone>314-286-1715</phone>
      <email>harous@anest.wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 13, 2016</lastchanged_date>
  <firstreceived_date>September 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>simon.haroutounian</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
